Showing 81 - 100 results of 2,852 for search '(( decrease host resistance ) OR ( ((decrease therapeutic) OR (derived therapeutics)) options ))', query time: 0.44s Refine Results
  1. 81
  2. 82
  3. 83
  4. 84
  5. 85
  6. 86
  7. 87
  8. 88

    Fig 4 - by Dirk Tänzler (658201)

    Published 2023
    Subjects:
  9. 89
  10. 90
  11. 91
  12. 92

    Fig 6 - by Dirk Tänzler (658201)

    Published 2023
    Subjects:
  13. 93
  14. 94

    DataSheet_1_Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics.pdf by Jie Zhang (64655)

    Published 2024
    “…Background<p>Adrenocortical carcinoma (ACC) is an aggressive endocrine malignancy with limited therapeutic options. Treating advanced ACC with mitotane, the cornerstone therapy, remains challenging, thus underscoring the significance to predict mitotane response prior to treatment and seek other effective therapeutic strategies.…”
  15. 95
  16. 96
  17. 97
  18. 98
  19. 99
  20. 100